The Role Of Hemoperfusion (PMX-DHP) In Children With Septic Shock

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

TCTR

Registry ID

TCTR20180418002

Enrollment

Registered

2018-04-18

Start date

2017-05-02

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sepsis or septic shock pediatric patient need vasopressor severity score mortality sepsis septic shock pediatric sepsis high mortality hemoperfusion

Interventions

hemoperfusion by special cartridge (PMX&#45

DHP) : it is a cartridge for hemoperfusion which coated with polymyxin B and special fiber that can separate endotoxin and cytokines out from blood

Experimental Device

hemoperfusion

Eligibility

Sex/Gender

All

Age

30 Days to 15 Years

Inclusion criteria

Inclusion criteria: -children age between 30days to 15 years who admitted in PICU,King chulalongkorn memorial hospital -Diagnosis severe sepsis or septic shock(definition by SCCM 2012 criteria) -PELOD-2 score >/= 10 or PRISM-3 scores >/=15 - need vasopressor or inotropic drug >/=1 type

Exclusion criteria

Exclusion criteria: -patient with end of life care -polymyxin allergy -contraindication for anticoagulation(uncontrolled bleeding, platelets<30,000)

Design outcomes

Primary

Measure	Time frame
clinical outcomes 24 hr, 48 hr, 72 hr PELOD and PRISM scores, inotropic score	—

Secondary

Measure	Time frame
clinical status 24 hr, 48 hr, 72 hr oxygenation index	—

Countries

Thailand

Contacts

Public Contactpatcharin trijaksang

Department of Pediatrics, Faculty of Medicine,Chulalongkorn university

patchamed@hotmail.com0835344503

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026

The Role Of Hemoperfusion (PMX&#45;DHP) In Children With Septic Shock